(NASDAQ: BDTX) Black Diamond Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Black Diamond Therapeutics's earnings in 2026 is $22,367,000.On average, 11 Wall Street analysts forecast BDTX's earnings for 2026 to be -$37,111,652, with the lowest BDTX earnings forecast at -$50,528,678, and the highest BDTX earnings forecast at -$16,241,361. On average, 10 Wall Street analysts forecast BDTX's earnings for 2027 to be -$54,934,182, with the lowest BDTX earnings forecast at -$111,163,091, and the highest BDTX earnings forecast at -$27,068,934.
In 2028, BDTX is forecast to generate -$49,646,431 in earnings, with the lowest earnings forecast at -$89,828,760 and the highest earnings forecast at -$28,271,998.